Safety group forewarned about Genentech drug name confusion
This article was originally published in Scrip
Executive Summary
Long before the FDA warned on 6 May about the risk of name confusion for two Genentech breast cancer drugs, the Institute for Safe Medications Practices (ISMP) was on the case, alerting health care professionals in its 7 March ISMP Medication Safety Alert.